More Prescient Therapeutics Limited news
Prescient Therapeutics LimitedASX: PTX

Receipt of R&D Tax Rebate

Nov 7, 2019 at 10:28 PM EST · Issued by Prescient Therapeutics Limited

Filed with ASX · Nov 7, 2019 at 10:28 PM EST · 3 pages · English

On 6ix: 6ix.com/news/receipt-of-randd-tax-rebate-1

Prescient Therapeutics Limited on 6ix

Earlier from Prescient Therapeutics

  • Prescient Ausbiotech Ras PresentationOct 30, 2019
  • September 2019 Appendix 4C - QuarterlyOct 29, 2019
  • Appendix 4E and 2019 Annual ReportAug 25, 2019
  • June 2019 Appendix 4C - QuarterlyJul 23, 2019
  • PTX Initiates Phase 1b Clinical Trial for PTX-100Jul 10, 2019

Later from Prescient Therapeutics

  • 1st patient dosed in trial for first in class drug PTX-100Nov 13, 2019
  • PTX in new CAR-T collaborationNov 17, 2019
  • Third complete response in PTX-200 AML TrialNov 26, 2019
  • Encouraging data from PTX-200 ovarian cancer trialDec 11, 2019
  • PTX-200 High Overall Response in Ph2a Breast Cancer trialDec 22, 2019
All Prescient Therapeutics news releases↗

Follow Prescient Therapeutics into a list and get an email when it puts out news.

Follow Prescient Therapeutics
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer